 Historically, vitamin K antagonists have been reversed using fresh frozen plasma FFP transfusions which, though effective, often incur delays due to the time required to obtain a type screen, thaw the product, and administer the product to the patient. In 2013, the FDA approved 4-factor prothrombin complex PCC, a concentrate of factors II, VII, IX, X, protein C and protein S for use as a method for correcting vitamin K antagonist related coagulopathy. Though large, prospective randomized control trials have demonstrated efficacy and safety in a general population of all-comers bleeding, there is very little literature regarding the benefits of PCC versus FFP in the traumatic and spontaneous intracranial hemorrhage population. 